Press release - 14/12/2022 New drug for metastatic prostate cancer now also approved in Europe On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen
Article - 14/09/2022 Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
Press release - 20/01/2023 Czech Inventor Award for Martina Benešová-Schäfer With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tschechischer-erfinderpreis-fuer-martina-benesova-schaefer
TWYCE GmbH - 10/07/2024 Better immune response against prostate cancer thanks to new bispecific antibodies TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
Translational oncology - 26/05/2020 Translation: driver of cancer medicine The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field. https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
Dossier - 05/11/2012 Cancer basic research successes and trends Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
Press release - 11/03/2021 Researchers recommend earlier start of breast cancer screening with family history of ovarian cancer Women have an increased risk of breast cancer if they have a family history of this disease. However, the risk may also be higher if first-degree family members have another type of cancer, according to a study by a team of scientists and physicians from the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), as well as international colleagues. https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-recommend-earlier-start-breast-cancer-screening-family-history-ovarian-cancer
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis